# Boston Scientific Corp. (BSX) stock analysis and sentiment Canonical page: https://synoptiv.com/stock/BSX Methodology: https://synoptiv.com/methodology Author: Synoptiv Research Engine Last analyzed: Aug 21, 2026 Boston Scientific Corp. (BSX) last closed at $52.01, near the bottom of its 52-week range of $42.20–$109.50. Composite market sentiment across 1 analysis is positive (+20 on a −100 to +100 scale), as of Aug 21, 2026. ## What the data says Boston Scientific closed at $52.01, sitting in the lower half of a 52-week band that runs from $42.20 to $109.50. That range is unusually wide for a large-cap medical device name — the high is more than double the low — and the current price is closer to the bottom of it, roughly 9 points above the trailing low and well below the highs the stock reached over the past year. The market capitalization stands at about $71.5 billion. At $52.01 the shares trade at roughly 21 times trailing earnings and about 14 times forward estimates, a gap that reflects expectations for earnings to grow from here rather than any change in the current price. Price to book sits near 2.9. The business itself carries a net profit margin of about 17.5% with revenue growing around 7.5% year over year, so the earnings supporting that multiple are real rather than marginal. Beta of 0.57 means the stock has historically moved a little over half as much as the broader market, which is typical of medical device companies whose demand is tied to procedure volumes rather than the economic cycle. Recent headlines have been mostly about the sector rather than the company. Most of the last two months' items are third-party market-sizing reports on electrosurgery, robotic endoscopy, urology devices, disposable endoscopes, and brain implants — the categories Boston Scientific competes in, but not news about Boston Scientific itself. The clearest company-specific item is an August 10 report that CEO Mahoney purchased more than 200,000 shares for roughly $10 million. The remaining items concern other firms in adjacent cardiac diagnostics. ## About Boston Scientific Corp. Boston Scientific Corporation develops, manufactures, and sells medical devices used in interventional medicine worldwide. The company reports in two segments, MedSurg and Cardiovascular. Its MedSurg business covers endoscopy, with tools for diagnosing and treating gastrointestinal and pancreaticobiliary conditions such as clips, stents, delivery systems, and single-use scopes; urology and pelvic health, including ureteral stents, catheters, guidewires, ureteroscopes, laser systems, and implants; and neuromodulation, including spinal cord stimulation, radiofrequency and nerve ablation, and deep brain stimulation systems for movement disorders and chronic pain. The Cardiovascular segment spans interventional cardiology, including devices for structural heart procedures such as left atrial appendage closure; cardiac rhythm management, with implantable defibrillators, pacemakers, insertable cardiac monitors, and remote monitoring systems; electrophysiology products for diagnosing and treating heart rhythm disorders; and peripheral interventions for arterial and venous disease, along with devices used in the diagnosis and treatment of certain cancers. Boston Scientific was incorporated in 1979 and is headquartered in Marlborough, Massachusetts. ## Company profile - Symbol: BSX - Exchange: NYSE - Security type: Stock - Sector: Healthcare - Industry: Medical Devices - Composite sentiment: positive (20 on a -100 to +100 scale) ## Key statistics | Metric | Value | | --- | ---: | | Market capitalization | $71.55B | | Enterprise value | $83.88B | | Trailing P/E | 21.01 | | Forward P/E | 14.36 | | Price to book | 2.87 | | Price to sales | 3.41 | | Beta | 0.57 | | Net margin | 17.50% | | Revenue growth | 7.50% | | Earnings growth | 15.10% | | 52-week high | $109.50 | | 52-week low | $42.20 | | Average volume | 20.81M | ## Related stocks - [ABT](https://synoptiv.com/stock/ABT) - [ISRG](https://synoptiv.com/stock/ISRG) - [SYK](https://synoptiv.com/stock/SYK) - [EW](https://synoptiv.com/stock/EW) - [BDX](https://synoptiv.com/stock/BDX) - [IDXX](https://synoptiv.com/stock/IDXX) - [DXCM](https://synoptiv.com/stock/DXCM) - [GEHC](https://synoptiv.com/stock/GEHC) - [RMD](https://synoptiv.com/stock/RMD) - [ZBH](https://synoptiv.com/stock/ZBH) ## Recent news - [Hedging Exposure In This Volatile Market](https://seekingalpha.com/article/4938927-hedging-exposure-in-this-volatile-market) — Aug 20, 2026 - [Boston Scientific Corp. stock underperforms Thursday when compared to competitors](https://www.marketwatch.com/data-news/boston-scientific-corp-stock-underperforms-thursday-when-compared-to-competitors-2360d555-a352866e640e?mod=mw_FV) — Aug 20, 2026 - [Boston Scientific (BSX) Faces Growth Concerns in Key Medical Device Franchises](https://finance.yahoo.com/healthcare/articles/boston-scientific-bsx-faces-growth-194823938.html) — Aug 17, 2026 - [If You Invested $1000 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today](https://www.benzinga.com/news/26/08/61250850/if-you-invested-1000-boston-scientific-stock-15-years-ago-you-would-have-much-today) — Aug 17, 2026 - [Boston Scientific (BSX), What Is Behind The Latest Investor Attention?](https://finance.yahoo.com/markets/stocks/articles/boston-scientific-bsx-behind-latest-050803683.html) — Aug 15, 2026 - [Is Boston Scientific’s (BSX) Buyback at Odds with Its Lower 2026 Growth Guidance?](https://finance.yahoo.com/markets/stocks/articles/boston-scientific-bsx-buyback-odds-031759033.html) — Aug 15, 2026 - [Is Boston Scientific (BSX) Still Undervalued After A 50% Fall?](https://finance.yahoo.com/markets/stocks/articles/boston-scientific-bsx-still-undervalued-221324138.html) — Aug 14, 2026 - [Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?](https://finance.yahoo.com/markets/stocks/articles/ew-stock-worth-buying-growth-153700042.html) — Aug 14, 2026 - [Get insights into the top movers in the S&P500 index of Friday's pre-market session.](https://www.chartmill.com/news/BSX/Chartmill-53608-Get-insights-into-the-top-movers-in-the-SP500-index-of-Fridays-pre-market-session) — Aug 14, 2026 - [Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead](https://seekingalpha.com/article/4936792-boston-scientific-a-deep-dive-into-the-headwinds-and-why-i-see-a-recovery-ahead) — Aug 14, 2026 ## Frequently asked questions ### What is the current market sentiment for BSX? As of Aug 21, 2026, Boston Scientific Corp. (BSX) carries positive (+20 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report. ### How has BSX stock been performing? Boston Scientific Corp. last closed at $52.01, near the bottom of its 52-week range of $42.20–$109.50. ### What is BSX's market cap and valuation? Boston Scientific Corp. has a market capitalization of about $71.55B, a trailing P/E of 21.0. ### What sector is BSX in, and who are its competitors? Boston Scientific Corp. operates in the Healthcare sector, specifically Medical Devices. Comparable companies include ABT, ISRG, SYK, EW, BDX. ### Where can I find a full analysis of BSX? The full BSX report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account. ## Important information This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice. - [Methodology](https://synoptiv.com/methodology) - [Disclosures](https://synoptiv.com/disclosures) - [Full report](https://synoptiv.com/stock/BSX/v/1) (account and access required)